Gils A - Search Results

1

Use of mouse models to study plasminogen activator inhibitor-1.

Declerck PJ, Gils A, De Taeye B. Declerck PJ, et al. Among authors: gils a. Methods Enzymol. 2011;499:77-104. doi: 10.1016/B978-0-12-386471-0.00005-5. Methods Enzymol. 2011. PMID: 21683250

2

Dose-dependent modulation of choroidal neovascularization by plasminogen activator inhibitor type I: implications for clinical trials.

Lambert V, Munaut C, Carmeliet P, Gerard RD, Declerck PJ, Gils A, Claes C, Foidart JM, Noël A, Rakic JM. Lambert V, et al. Among authors: gils a. Invest Ophthalmol Vis Sci. 2003 Jun;44(6):2791-7. doi: 10.1167/iovs.02-1179. Invest Ophthalmol Vis Sci. 2003. PMID: 12766088 Free article.

3

Tryptophan properties in fluorescence and functional stability of plasminogen activator inhibitor 1.

Verheyden S, Sillen A, Gils A, Declerck PJ, Engelborghs Y. Verheyden S, et al. Among authors: gils a. Biophys J. 2003 Jul;85(1):501-10. doi: 10.1016/S0006-3495(03)74495-6. Biophys J. 2003. PMID: 12829505 Free PMC article.

4

Biochemical importance of glycosylation of plasminogen activator inhibitor-1.

Gils A, Pedersen KE, Skottrup P, Christensen A, Naessens D, Deinum J, Enghild JJ, Declerck PJ, Andreasen PA. Gils A, et al. Thromb Haemost. 2003 Aug;90(2):206-17. doi: 10.1160/TH03-01-0034. Thromb Haemost. 2003. PMID: 12888867

5

The structural basis for the pathophysiological relevance of PAI-I in cardiovascular diseases and the development of potential PAI-I inhibitors.

Gils A, Declerck PJ. Gils A, et al. Thromb Haemost. 2004 Mar;91(3):425-37. doi: 10.1160/TH03-12-0764. Thromb Haemost. 2004. PMID: 14983217 Review.

6

Comparative analysis of the proteinase specificity in wild-type and stabilized plasminogen activator inhibitor-1: evidence for contribution of intramolecular flexibility.

De Taeye B, Gils A, Vleugels N, Rabijns A, Declerck PJ. De Taeye B, et al. Among authors: gils a. Biochem Biophys Res Commun. 2004 Aug 27;321(3):746-51. doi: 10.1016/j.bbrc.2004.07.023. Biochem Biophys Res Commun. 2004. PMID: 15358169

7

Plasminogen activator inhibitor-1.

Gils A, Declerck PJ. Gils A, et al. Curr Med Chem. 2004 Sep;11(17):2323-34. doi: 10.2174/0929867043364595. Curr Med Chem. 2004. PMID: 15379715 Review.

8

The story of the serpin plasminogen activator inhibitor 1: is there any need for another mutant?

De Taeye B, Gils A, Declerck PJ. De Taeye B, et al. Among authors: gils a. Thromb Haemost. 2004 Nov;92(5):898-924. doi: 10.1160/TH04-05-0269. Thromb Haemost. 2004. PMID: 15543316 Review.

9

Subtle structural differences between human and mouse PAI-1 reveal the basis for biochemical differences.

Dewilde M, Van De Craen B, Compernolle G, Madsen JB, Strelkov S, Gils A, Declerck PJ. Dewilde M, et al. Among authors: gils a. J Struct Biol. 2010 Jul;171(1):95-101. doi: 10.1016/j.jsb.2010.03.006. Epub 2010 Mar 15. J Struct Biol. 2010. PMID: 20230900

10

Characterization of a panel of monoclonal antibodies toward mouse PAI-1 that exert a significant profibrinolytic effect in vivo.

Van De Craen B, Scroyen I, Abdelnabi R, Brouwers E, Lijnen HR, Declerck PJ, Gils A. Van De Craen B, et al. Among authors: gils a. Thromb Res. 2011 Jul;128(1):68-76. doi: 10.1016/j.thromres.2011.01.011. Epub 2011 Mar 9. Thromb Res. 2011. PMID: 21392818

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

320 results

Search Page

Filters